Cabaletta Bio(CABA) - 2025 Q1 - Quarterly Results

Form 8-K Current Report Results of Operations and Financial Condition Cabaletta Bio disclosed its cash position as of March 31, 2025, was $131.8 million, down from $164.0 million at the end of 2024. The company expects its current cash reserves to fund operations into the first half of 2026 Cash and Cash Equivalents | Metric | As of March 31, 2025 | As of December 31, 2024 | | :--- | :--- | :--- | | Cash and Cash Equivalents | $131.8 million | $164.0 million | - The company projects its cash position as of March 31, 2025, will be sufficient to fund its operating plan into the first half of 2026[6] Regulation FD Disclosure On May 15, 2025, the company made two key disclosures: it posted an updated corporate presentation on its website and issued a press release announcing an anticipated 2027 BLA submission for Rese-cel in Myositis - An updated corporate presentation was posted to the "Investors & Media" section of the company's website on May 15, 2025[8] - The company issued a press release announcing its plan to submit a BLA for Rese-cel in Myositis in 2027 after reaching an alignment with the FDA on registrational cohorts[9] Financial Statements and Exhibits This section lists the exhibits furnished with the Form 8-K filing, which include the press release from May 15, 2025, and the Cover Page Interactive Data File - The following exhibits were filed with the report: - Exhibit 99.1: Press Release issued on May 15, 2025 - Exhibit 104: Cover Page Interactive Data File[11]